|
gptkbp:instanceOf
|
gptkb:company
gptkb:public_company
|
|
gptkbp:abbreviation
|
gptkb:Laboratory_Corporation_of_America_Holdings
|
|
gptkbp:acquiredBy
|
gptkb:Covance
|
|
gptkbp:acquisitionYear
|
2015
|
|
gptkbp:CEO
|
gptkb:Adam_H._Schechter
|
|
gptkbp:competitor
|
gptkb:Quest_Diagnostics
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
50540R409
|
|
gptkbp:divested
|
2021
Covance clinical development business
|
|
gptkbp:founded
|
1978
|
|
gptkbp:foundedBy
|
gptkb:James_B._Powell
gptkb:Matthew_B._Coffey
gptkb:Thomas_P._Mac_Mahon
|
|
gptkbp:founder
|
gptkb:Reynolds_Medical_Laboratory
|
|
gptkbp:headquartersLocation
|
gptkb:Burlington,_North_Carolina,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
LabCorp
|
|
gptkbp:industry
|
healthcare
diagnostics
|
|
gptkbp:ISIN
|
US50540R4092
|
|
gptkbp:laboratoryNetwork
|
gptkb:United_States
international
|
|
gptkbp:legalForm
|
public
|
|
gptkbp:logo
|
LabCorp logo.svg
|
|
gptkbp:marketCap
|
over $20 billion (2023)
|
|
gptkbp:notableProduct
|
COVID-19 testing
genetic testing
toxicology testing
clinical trial services
oncology testing
|
|
gptkbp:numberOfEmployees
|
over 75,000
|
|
gptkbp:numberOfLocations
|
over 2,000 patient service centers
|
|
gptkbp:numberOfTestsPerformedAnnually
|
over 500 million
|
|
gptkbp:parentCompany
|
gptkb:Laboratory_Corporation_of_America_Holdings
|
|
gptkbp:revenue
|
$14.88 billion (2022)
|
|
gptkbp:S&P500Component
|
no
yes
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:services
|
clinical laboratory services
drug development services
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:NYSE
gptkb:LH
|
|
gptkbp:subsidiary
|
gptkb:Covance
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.labcorp.com/
|
|
gptkbp:bfsParent
|
gptkb:Quest_Diagnostics
gptkb:Burlington,_North_Carolina,_United_States
|
|
gptkbp:bfsLayer
|
5
|